Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Vivos Therapeutics, Inc.

CIK 1716166 VVOS·Medical Instruments · All EDGAR filings ↗

Progression

  1. Late filing NT 10-K
  2. Finance chief departure 8-K +125d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure Filing comparison

Vivos Therapeutics, Inc.'s Chief Financial Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Late filing elevated Filing comparison

Vivos Therapeutics, Inc. filed its quarterly report late and said it expects a significant change in results

expects significant change in results Filed on the statutory due date.

(the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) within the prescribed time period without undue hardship and expense because the compilation, dissemination and review of the information required to be properly presented in the Form 10-Q. As of the date hereof, the Company and its independent registered public accounting firm requires additional time to complete the review of SCN’s interim financial statements and to consolidate such financial statements into the Company’s unaudited financial statements for the quarter ended March 31, 2026.
Evidence
Anticipates significant change
Yes
Days past due date
0
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) within the prescribed time period without undue hardship and expense because the compilation, dissemination and review of the information required to be properly presented in the Form 10-Q. As of the date hereof, the Company and its independent registered public accounting firm requires additional time to complete the review of SCN’s interim financial statements and to consolidate such financial statements into the Company’s unaudited financial statements for the quarter ended March 31, 2026.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Late filing elevated Filing comparison

Vivos Therapeutics, Inc. filed its annual report late and said it expects a significant change in results

expects significant change in results Filed on the statutory due date.

(the “Company”) is unable to file its Form 10-K for the year ended December 31, 2025 (the “Form 10-K”) within the prescribed time period without undue hardship and expense because the compilation, dissemination and review of the information required to be properly presented in the Form 10-K, particularly related to the Company’s 2025 acquisition of Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”), and certain SCN-related matters. As a result, the Company requires additional time to complete its year-end financial statements and related disclosures. The Company expects to file the Form 10-K within the prescribed extension period.
Evidence
Anticipates significant change
Yes
Days past due date
0
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) is unable to file its Form 10-K for the year ended December 31, 2025 (the “Form 10-K”) within the prescribed time period without undue hardship and expense because the compilation, dissemination and review of the information required to be properly presented in the Form 10-K, particularly related to the Company’s 2025 acquisition of Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”), and certain SCN-related matters. As a result, the Company requires additional time to complete its year-end financial statements and related disclosures. The Company expects to file the Form 10-K within the prescribed extension period.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗